β-cell preservation: A potential role for thiazolidinediones to improve clinical care in Type 2 diabetes

Diabetic Medicine

Volumn 22, Issue 8, 2005, Pages 963-972

  Leiter, Lawrence A ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Glycaemic control; Mechanisms of cell dysfunction; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLIN; CYTOKINE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

CELL FUNCTION; DISEASE PREDISPOSITION; EDEMA; FATTY ACID BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; THIAZOLIDINEDIONES;

EID: 22644440448     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01605.x     Document Type: Review

References (98)

1. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
2. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
3. Tyrberg B, Levine F. Current and future treatment strategies for type 2 diabetes: the beta-cell as a therapeutic target. Curr Opin Invest Drugs 2001; 2: 1568-1574.
4. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest 2002; 32: 14-23.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
7. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-296.
8. Holman RR. Assessing the potential for α-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40: S21-S25.
9. Bagust A, Beale S. Deteriorating β-cell function in type 2 diabetes: a long-term model. Quart J Med 2003; 96: 281-288.
10. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999; 281: 2005-2012.
11. Matthews DR. Insulin resistance and β-cell function-a clinical perspective. Diabetes Obes Metab 2001; 3: S28-S33.
12. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
13. Alberti KGMM. Treating type 2 diabetes-today's targets, tomorrow's goals. Diabetes Obes Metab 2001; 3: S3-S10.
14. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403-408.
15. Liebl A. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45: S23-S28.
16. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003; 26: S33-S50.
17. American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2002 update. Endocr Pract 2002; 8: 40-82.
18. National Institute for Clinical Excellence. Clinical Guideline G. Management of Type 2 diabetes: Management of Blood Glucose. London: National Institute for Clinical Excellence 2002.
19. European Diabetes Policy Group. A desktop guide to Type 2 diabetes. Diabet Med 1999; 16: 716-730.
20. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27: S18-S20.
21. Reusch JE, Gadsby R. Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes. Diabetes Technol Ther 2003; 5: 685-693.
22. Wyne KL, Drexler AJ, Miller JL, Bell DS, Braunstein S, Nuckolls JG. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. Postgrad Med 2003: Special Report, 63-72.
23. Pick A, Clark J, Kubstrup C, Levisetti M, Pugh W, Bonner-Weir S et al. Role of apoptosis in failure of β-cell mass compensation for insulin resistance and β-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998; 47: 358-364.
24. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
25. Pfeifer MA, Halter JB, Porte DJ. Insulin secretion in diabetes mellitus. Am J Med 1981; 70: 579-588.
26. Kahn SE. β-Cell failure: causes and consequences. Int J Clin Pract 2001; 123: 13-18.
27. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study. Diabetes Care 2003; 26: 868-874.
28. Halban PA. Structural domains and molecular lifestyles of insulin and its precursors in the pancreatic β cell. Diabetologia 1991; 34: 767-778.
29. Kahn SE. Regulation of β-cell function in vivo: from health to disease. Diabetes Rev 1996; 4: 372-389.
30. Røder ME, Porte DJ, Schwartz RS, Kahn SE. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998; 83: 604-608.
31. Pradhan AD, Manson JE, Meigs JB, Rifai N, Buring JE, Liu S et al. Insulin, proinsulin, proinsulin: insulin ratio, and the risk of developing type 2 diabetes mellitus in women. Am J Med 2003; 114: 438-444.
32. Bergman RN, Finegood DT, Kahn SE. The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002; 32: 35-45.
33. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
34. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
35. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
36. Fukushima M, Taniguchi A, Sakai M, Doi K, Nagasaka S, Tanaka H et al. Homeostasis model assessment as a clinical index of insulin resistance. Comparison with the minimal model analysis. Diabetes Care 1999; 22: 1911-1912.
37. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-1092.
38. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 1643-1649.
39. Sesti G. Searching for type 2 diabetes genes: prospects in pharmacotherapy. Pharmacogenomics J 2002; 2: 25-29.
40. Sesti G, Cardellini M, Marini MA, Frontoni S, D'Adamo M, Del Guerra S et al. A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. Diabetes 2003; 52: 1280-1283.
41. Rhodes CJ, White MF. Molecular insights into insulin action and secretion. Eur J Clin Invest 2002; 32: 3-13.
42. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and β-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32: 24-34.
43. Östgren CJ, Lindblad U, Ranstam J, Melander A, Rastam L. Glycaemic control, disease duration and β-cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project. Diabet Med 2002; 19: 125-129.
44. Finegood DT, Topp B. β-cell deterioration-prospects for reversal or prevention. Diabetes Obes Metab 2001; 3: S20-S27.
45. Leahy JL, Bonner-Weir S, Weir GC. β-Cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992; 15: 442-455.
46. Purrello F, Rabuazzo AM, Anello M, Patane G. Effects of prolonged glucose stimulation on pancreatic β cells: from increased sensitivity to desensitization. Acta Diabetol 1996; 33: 253-256.
47. Federici M, Hribal M, Perego L, Ranalli M, Caradonna Z, Perego C et al. High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes 2001; 50: 1290-1301.
48. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A et al. Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes 2001; 50: 1683-1690.
49. Arner P. Free fatty acids-do they play a central role in type 2 diabetes? Diabetes Obes Metab 2001; 3: S11-S19.
50. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced β cell apoptosis. a link between obesity and diabetes. Proc Natl Acad Sci USA 1998; 95: 2498-2502.
51. Furukawa H, Carroll RJ, Swift HH, Steiner DF. Long-term elevation of free fatty acids leads to delayed processing of proinsulin and prohormone convertases 2 and 3 in the pancreatic β-cell line MIN6. Diabetes 1999; 48: 1395-1401.
52. Bollheimer LC, Skelly RH, Chester MW, McGarry JD, Rhodes CJ. Chronic exposure to free fatty acid reduces pancreatic β cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthesis translation. J Clin Invest 1998; 101: 1094-1101.
53. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. β-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-β-cell relationships. Proc Natl Acad Sci USA 1994; 91: 10878-10882.
54. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003; 52: 2461-2471.
55. Peraldi P, Spiegelman B. TNF-α and insulin resistance: summary and future prospects. Mol Cell Biochem 1998; 182: 169-175.
56. 2 and aminoguanidine. A role for peroxisome proliferator-activated receptor γ activation and iNOS expression. J Biol Chem 1999; 274: 18702-18708.
57. Clark A, Charge SB, Badman MK, de Koning EJ. Islet amyloid in type 2 (non-insulin-dependent) diabetes. APMIS 1996; 104: 12-18.
58. Hull RL, Andrikopoulos S, Verchere CB, Vidal J, Wang F, Cnop M et al. Increased dietary fat promotes islet amyloid formation and β-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes 2003; 52: 372-379.
59. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999; 48: 491-498.
60. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
61. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-1611.
62. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000; 17: 40-47.
63. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111: 10-17.
64. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J Am Med Assoc 2000; 283: 1695-1702.
65. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000; 22: 1395-1409.
66. Pavo I, Jermendy G, Varkonyi TT, Kerenyi Z, Gyimesi A, Shoustov S et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 1637-1645.
67. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-170.
68. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-423.
69. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-719.
70. Smith SA. Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism. Biochem Soc Trans 2002; 30: 1086-1090.
71. Masamune A, Kikuta K, Satoh M, Sakai Y, Satoh A, Shimosegawa T. Ligands of peroxisome proliferator-activated receptor-γ block activation of pancreatic stellate cells. J Biol Chem 2002; 277: 141-147.
72. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004; 286: E560-E567.
73. Szalkowski D, White-Carrington S, Berger J, Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 1995; 136: 1474-1481.
74. Campbell IW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004; 58: 192-200.
75. Nadra AR, Freeman K, Ambery PD. Long-term glycaemic control with rosiglitazone as monotherapy. Diabet Med 2004; 21: 65.
76. Zinman B. PPARγ agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab 2001; 3: S34-S43.
77. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal β-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004; 21: 568-576.
78. Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 56-59.
79. Ovalle F, Bell DSH. Effect of rosiglitazone vs insulin on the pancreatic β-cell function of subjects with type 2 diabetes mellitus. Diabetes 2003; 52: A130.
80. Juhl CB, Hollingdal M, Porksen N, Prange A, Lonnqvist F, Schmitz O. Influence of rosiglitazone treatment on β-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003; 88: 3794-3800.
81. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-821.
82. Scheen AJ. Glitazones and weight gain. Ann Endocrinol (Paris) 2002; 63: IS412-IS414.
83. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003; 115: 42S-48S.
84. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948.
85. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2000; 2: 363-372.
86. Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta H et al. Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice: Possible protection of β cells from oxidative stress. Metabolism 2004; 53: 488-494.
87. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100: 530-537.
88. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-1193.
89. Bennett SM, Agrawal A, Elasha H, Heise M, Jones NP, Walker M et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 2004; 21: 415-422.
90. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004; 6: 280-285.
91. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A et al. Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 2000; 49: 782-788.
92. Buchanan TA. Pancreatic β-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 989-993.
93. Rockville M. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program (DPP). Diabetes 2003; 52: A58.
94. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR et al. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737-1743.
95. Xiang A, Peters R, Kjos S, Goiko J, Roquin A, Ochoa C et al. Continued protection from diabetes during treatment of the TRIPOD Cohort with pioglitazone. Diabetes 2003; 52: A75.
96. Adler AI. Cardiovascular risk reduction in diabetes: underemphasised and overdue. Messages from major trials. Clin Med 2001; 1: 472-477.
97. Kerenyi Z, Samer H, Yan Y, Stewart M. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004; 63: 213-223.
98. Baksi A, James RE, Zhou B, Nolan JJ. Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of sulphonylurea. Acta Diabetol 2004; 41: 63-69.